Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Basaglar

China flag thumb

Sanofi and Lilly also visited by Chinese authorities

Follows GSK bribery allegations

- PMLiVE

Boehringer: clinical trial set-up poses challenge in rare diseases

Says more support needed in regulatory process for orphan drugs

Sanofi reception

Sanofi cuts forecasts but says worst effects of patent cliff have passed

Sales continue to fall on generic competition and mismanagement in Brazil affects emerging markets

- PMLiVE

Executive changes at Sanofi

Genzyme CEO Meeker becomes executive VP and Hellmann joins to lead animal health

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Lonza ends biosimilars deal with Teva

Chemical firm cuts losses after four-year development deal

Sanofi Israel crowdsources new diabetes app

Collaborates with online patient network Camoni

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

- PMLiVE

US increases pressure on India over generics industry

Follows complaints from Pfizer about the country’s patent laws

- PMLiVE

First mAb biosimilars set for European approval

Celltrion and Hospira's versions of J&J's blockbuster Remicade recommended by CHMP

Sanofi reception

Sanofi wins Japanese approval for diabetes drug Lyxumia

Becomes first treatment of its class licensed in combination with basal insulin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links